

Cover Story
By Matthew Bin Han Ong
The FDA Molecular and Clinical Genetics Panel voted 10-0 to recommend approval of Cologuard—a noninvasive, multitarget stool DNA screening test for colorectal cancer.
In Brief


Trending Stories
- Tidmarsh is out, Pazdur is in: FDA’s CDER under new leadership
- Christine Lovly to lead City of Hope’s new national thoracic oncology program
- CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”
Cancer advocates express concern about comments that signal trouble for accelerated approval - Mary Pazdur, 63, Dies of Cancer; What Her Husband Has Learned
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- FDA to remove black box warnings on hormone therapy for menopause
Trump-era “gold standard science” is not to be confused with gold standard of scientific evidence










